NEW YORK, Sept. 11, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback